Secondary failure of platelet recovery after hematopoietic stem cell transplantation.

After primary recovery of platelet counts after transplantation, there can be a late persistent decline called secondary failure of platelet recovery (SFPR), which may occur although the counts of other cell lineages remain within the normal range. SFPR was defined as a decline of platelet counts below 20,000/microL for 7 consecutive days or requiring transfusion support after achieving sustained platelet counts > or = 50,000/microL without transfusions for 7 consecutive days after hematopoietic stem cell transplantation (HSCT). The study population consisted of 2871 consecutive patients receiving transplants from January 1990 to March 1997. After primary recovery of platelet counts, SFPR not due to relapse of the underlying disease was observed in 285 of 1401 (20%) patients undergoing allogeneic transplantation and 36 (8%) of 444 patients undergoing autologous transplantation, with a median time of onset after transplantation at day 63 (range, day 21-156) and day 44 (range, day 24-89), respectively. Concomitant neutropenia was seen in 57 (20%) of 285 patients undergoing allogeneic HSCT and 7 (19%) of 36 patients undergoing autologous HSCT with SFPR. By multivariable analysis, the following were factors significantly associated with SFPR after allogeneic HSCT: a transplant from an unrelated donor; a graft-versus-host disease (GVHD) prophylaxis other than methotrexate and cyclosporine; development of grade 2 through 4 acute GVHD; impaired renal or liver function; conditioning with the combination of busulfan, cyclophosphamide, and total body irradiation; stem cell dose; and infections. Cytomegalovirus infection after engraftment and source of stem cells were the only significant risk factors after autologous HSCT. The hazard rate of death was significantly higher in patients who experienced SFPR (hazard ratio = 2.6 for allogeneic HSCT; hazard ratio = 2.2 for autologous HSCT). SFPR was associated with serious complications and poor outcome after transplantation. The identification of the characteristics and risk factors for SFPR could improve patient counseling and management and lead to the design of effective treatment strategies.

[1]  J. Maciejewski,et al.  In vitro infection of megakaryocytes and their precursors by human cytomegalovirus. , 2000, Blood.

[2]  J. Vose,et al.  A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. , 1998, Blood.

[3]  J. Levin,et al.  Transient thrombocytopenia produced by administration of macrophage colony-stimulating factor: investigations of the mechanism. , 1998, Blood.

[4]  W. Leisenring,et al.  Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. , 1997, Blood.

[5]  R Storb,et al.  Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. , 1997, Blood.

[6]  G. Herzig,et al.  Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. , 1997, Seminars in hematology.

[7]  R. Storb,et al.  Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. , 1996, Blood.

[8]  F. Appelbaum,et al.  The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation , 1996, The oncologist.

[9]  R. Storb,et al.  Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. , 1996, Blood.

[10]  G. Remuzzi,et al.  The pathophysiology and management of thrombotic thrombocytopenic purpura , 1996, European journal of haematology.

[11]  J. Wingard,et al.  Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. , 1995, Bone marrow transplantation.

[12]  H. Deeg,et al.  Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: increased destruction of circulating platelets. , 1995, Blood.

[13]  R. Fisher,et al.  Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Pettitt,et al.  Thrombotic microangiopathy following bone marrow transplantation. , 1994, Bone marrow transplantation.

[15]  J. Moake.  Haemolytic-uraemic syndrome: basic science , 1994, The Lancet.

[16]  J. Vernant,et al.  Influence du statut clinique sur l'efficacité transfusionnelle des plaquettes conservées , 1993 .

[17]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[18]  B. Levine,et al.  Clinical and histopathological effects of M-CSF in laboratory animals. , 1993, International review of experimental pathology.

[19]  M. Sanda,et al.  Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Young,et al.  Infection of hematopoietic progenitor cells by human cytomegalovirus. , 1992, Blood.

[21]  R. Gascoyne,et al.  Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. , 1991, Bone marrow transplantation.

[22]  J. Nemunaitis,et al.  Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. , 1991, Blood.

[23]  H. Nieuwenhuis,et al.  Cytomegalovirus infection causes delayed platelet recovery after bone marrow transplantation , 1991 .

[24]  J. Gribben,et al.  Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. , 1991, Blood.

[25]  Johnson Pr,et al.  Thrombotic thrombocytopenic purpura following allogeneic bone marrow transplantation. , 1991, Bone marrow transplantation.

[26]  H. Prentice,et al.  The use of GM-CSF as an adjunct to autologous/syngeneic bone marrow transplantation: a prospective randomized controlled trial. , 1991 .

[27]  D. Weisdorf,et al.  Hemolytic uremic syndrome following bone marrow transplantation. , 1991, Bone marrow transplantation.

[28]  G. Sing,et al.  Preferential suppression of myelopoiesis in normal human bone marrow cells after in vitro challenge with human cytomegalovirus. , 1990, Blood.

[29]  W. Lehmacher,et al.  Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. , 1989, Blood.

[30]  C. Anasetti,et al.  Graft-v-host disease is associated with autoimmune-like thrombocytopenia. , 1989, Blood.

[31]  E. Matutes,et al.  The effect of cytomegalovirus on hemopoiesis: in vitro evidence for selective infection of marrow stromal cells. , 1989, Experimental hematology.

[32]  Jean E. Sanders,et al.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. , 1988, Blood.

[33]  R. Zittoun,et al.  Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. , 1986, Blood.

[34]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[35]  G. D. de Gast,et al.  Delay in platelet recovery after bone marrow transplantation: impact of cytomegalovirus infection. , 1985, Blood.

[36]  T. Poskitt,et al.  Thrombocytopenia of sepsis. The role of circulating IgG-containing immune complexes. , 1985, Archives of internal medicine.

[37]  J. Lipton,et al.  Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. , 1985, Blood.

[38]  F. Gardner,et al.  Thrombocytopenia as a laboratory sign and complication of gram-negative bacteremic infection. , 1966, Archives of internal medicine.

[39]  C S PETTY,et al.  NORMAL VARIATIONS WITH AGING OF THE AMOUNT OF HEMATOPOIETIC TISSUE IN BONE MARROW FROM THE ANTERIOR ILIAC CREST. A STUDY MADE FROM 177 CASES OF SUDDEN DEATH EXAMINED BY NECROPSY. , 1965, American journal of clinical pathology.